Molecular determinants underlying herceptin sensitivity and resistance
赫赛汀敏感性和耐药性的分子决定因素
基本信息
- 批准号:8737478
- 负责人:
- 金额:$ 17.07万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-07-01 至 2016-06-30
- 项目状态:已结题
- 来源:
- 关键词:AccountingAdjuvant TherapyBindingBiologicalBiological AssayBiological ProcessBreast Cancer CellCancer PatientCell AgingCell CycleCell Cycle ArrestCell LineCell ProliferationCellsCessation of lifeDNA DamageDatabasesDevelopmentEnzymesEpidermal Growth Factor ReceptorErbB Receptor Family ProteinExhibitsFibroblastsFluorescent in Situ HybridizationFoundationsFunctional disorderFutureGalactosidaseGenesGrowthHumanIGFBP3 geneIGFBP5 geneImmunohistochemistryInsulin-Like-Growth Factor I ReceptorIntegral Membrane ProteinLesionMalignant NeoplasmsMalignant neoplasm of ovaryMediatingMediator of activation proteinMolecularMolecular AnalysisMonoclonal AntibodiesMorphologyNamesOncogene ActivationOncogenicPathway interactionsPatientsPhenotypePhosphorylationPlatelet-Derived Growth Factor ReceptorPremalignantProcessProliferatingProtein Tyrosine KinaseProteinsReceptor InhibitionReceptor Protein-Tyrosine KinasesReceptor SignalingRecombinantsRecurrenceResearchResistanceResistance developmentRoche brand of trastuzumabSignal PathwayTherapeuticTrastuzumabTreatment EfficacyTumor Cell LineTumor-DerivedUnited StatesUp-RegulationUterine CancerWomanXenograft procedurebasecell growthclinical efficacycombatinhibitor/antagonistmalignant breast neoplasmmalignant stomach neoplasmmemberoutcome forecastoverexpressionprematurepublic health relevancereceptor expressionresearch studyresponsesenescencestandard of caretelomeretherapeutic targettumortumor progressiontumorigenesis
项目摘要
DESCRIPTION (provided by applicant): Herceptin/trastuzumab is a monoclonal antibody that selectively targets the Her2 protein and remains the standard of care for Her2-positive breast cancer. Nevertheless, the biological processes altered by trastuzumab to impede cancer progression are presently unclear. Results from our preliminary studies show that trastuzumab causes cellular senescence in both cultured breast cancer cells and tumors derived from human patients who have undergone treatment in adjuvant therapy. This observed senescent phenotype is associated with several hallmarks of senescence including an inability to proliferate, induction of the cell cycle inhibitors p16 and p21, senescence-associated ?-galactosidase activity, and upregulation of the secreted proteins IGFBP3 and IGFBP5. Previous studies have indicated that high-level expression of the insulin-like growth factor 1 receptor (IGF1R) is associated with a lower response rate to trastuzumab. Consistent with this, elevated levels of IGF1R expression and phosphorylation were found in trastuzumab-resistant breast cancer cells following Her2 inhibition. Importantly, trastuzumab resistance can be overcome by combining trastuzumab with either a selective IGF1R inhibitor or recombinant IGFBPs, resulting in cellular senescence. Collectively, these results reveal the biological underpinnings of trastuzumab's clinical efficacy and suggest a practical approach for the treatment of Her2-positive, trastuzumab-resistant breast cancer. Capitalizing on these new findings, we propose the following two specific aims to explore the molecular basis that distinguish breast cancer patients who are sensitive to trastuzumab from those who are resistant. Aim 1 will assess the potential contributions of several mechanisms that may control the expression level of IGF1R associated with sensitivity/resistance to trastuzumab. Aim 2 will explore whether tyrosine kinase receptors, in addition to IGF1R, could be involved in the development of a trastuzumab-resistant phenotype. Together results from these exploratory experiments will lay the foundation a systemic analysis of molecular determinants at the mechanistic level for sensitivity and resistant to this standard therapy for Her2-positive breast cancer can be conducted in the future.
描述(由申请方提供):赫赛汀/曲妥珠单抗是一种选择性靶向Her 2蛋白的单克隆抗体,仍是Her 2阳性乳腺癌的标准治疗。然而,目前尚不清楚曲妥珠单抗改变生物学过程以阻止癌症进展。我们的初步研究结果表明,曲妥珠单抗在培养的乳腺癌细胞和来自接受辅助治疗的人类患者的肿瘤中均引起细胞衰老。这种观察到的衰老表型与衰老的几个标志有关,包括不能增殖,诱导细胞周期抑制剂p16和p21,衰老相关的?半乳糖苷酶活性,以及分泌蛋白IGFBP 3和IGFBP 5的上调。先前的研究表明,胰岛素样生长因子1受体(IGF 1 R)的高水平表达与曲妥珠单抗的较低反应率相关。与此一致,在Her 2抑制后,在曲妥珠单抗耐药乳腺癌细胞中发现IGF 1 R表达和磷酸化水平升高。重要的是,曲妥珠单抗耐药性可以通过曲妥珠单抗与选择性IGF 1 R抑制剂或重组IGFBPs组合来克服,从而导致细胞衰老。总的来说,这些结果揭示了曲妥珠单抗临床疗效的生物学基础,并提出了治疗Her 2阳性、曲妥珠单抗耐药乳腺癌的实用方法。利用这些新发现,我们提出了以下两个具体目标,以探索区分对曲妥珠单抗敏感的乳腺癌患者与耐药患者的分子基础。目的1将评估可能控制与曲妥珠单抗敏感性/耐药相关的IGF 1 R表达水平的几种机制的潜在贡献。目的2将探讨酪氨酸激酶受体,除了IGF 1 R,是否可能参与曲妥珠单抗耐药表型的发展。这些探索性实验的结果将为将来对Her 2阳性乳腺癌标准疗法的敏感性和耐药性在机制水平上进行分子决定因素的系统分析奠定基础。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
XIAO-FAN WANG其他文献
XIAO-FAN WANG的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('XIAO-FAN WANG', 18)}}的其他基金
Roles of mitochondrial dynamics and mtDNA in senescence
线粒体动力学和 mtDNA 在衰老中的作用
- 批准号:
10641668 - 财政年份:2022
- 资助金额:
$ 17.07万 - 项目类别:
Roles of mitochondrial dynamics and mtDNA in senescence
线粒体动力学和 mtDNA 在衰老中的作用
- 批准号:
10344369 - 财政年份:2022
- 资助金额:
$ 17.07万 - 项目类别:
Roles of mitochondrial dynamics and mtDNA in senescence
线粒体动力学和 mtDNA 在衰老中的作用
- 批准号:
10795145 - 财政年份:2022
- 资助金额:
$ 17.07万 - 项目类别:
NGF recruits nerve fibers to reprogram an immunosuppressive microenvironment in melanoma
NGF 招募神经纤维来重新编程黑色素瘤中的免疫抑制微环境
- 批准号:
10552544 - 财政年份:2020
- 资助金额:
$ 17.07万 - 项目类别:
Synthetic lethality by targeting the core senescent mechanism in lung cancer.
针对肺癌核心衰老机制的综合致死率。
- 批准号:
10558746 - 财政年份:2020
- 资助金额:
$ 17.07万 - 项目类别:
Synthetic lethality by targeting the core senescent mechanism in lung cancer.
针对肺癌核心衰老机制的综合致死率。
- 批准号:
10368019 - 财政年份:2020
- 资助金额:
$ 17.07万 - 项目类别:
NGF recruits nerve fibers to reprogram an immunosuppressive microenvironment in melanoma
NGF 招募神经纤维来重新编程黑色素瘤中的免疫抑制微环境
- 批准号:
10321215 - 财政年份:2020
- 资助金额:
$ 17.07万 - 项目类别:
Targeting UHRF1 in combinational immunotherapy
联合免疫治疗中的靶向 UHRF1
- 批准号:
10308390 - 财政年份:2019
- 资助金额:
$ 17.07万 - 项目类别:
Targeting UHRF1 in combinational immunotherapy
联合免疫疗法中靶向 UHRF1
- 批准号:
10545165 - 财政年份:2019
- 资助金额:
$ 17.07万 - 项目类别:
相似海外基金
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
- 批准号:
10735090 - 财政年份:2023
- 资助金额:
$ 17.07万 - 项目类别:
The ESCAPE clinical trial of circulating tumor DNA to guide adjuvant therapy in chemo-resistant triple negative breast cancer
循环肿瘤 DNA 指导化疗耐药三阴性乳腺癌辅助治疗的 ESCAPE 临床试验
- 批准号:
494901 - 财政年份:2023
- 资助金额:
$ 17.07万 - 项目类别:
Operating Grants
A Type I Hybrid Effectiveness-Implementation Trial to Evaluate a Navigation-Based Multilevel Intervention to Decrease Delays Starting Adjuvant Therapy Among Patients with Head and Neck Cancer
一项 I 型混合有效性实施试验,用于评估基于导航的多级干预措施,以减少头颈癌患者开始辅助治疗的延迟
- 批准号:
10714537 - 财政年份:2023
- 资助金额:
$ 17.07万 - 项目类别:
Multi-modal machine learning to guide adjuvant therapy in surgically resectable colorectal cancer
多模式机器学习指导可手术切除结直肠癌的辅助治疗
- 批准号:
10588103 - 财政年份:2023
- 资助金额:
$ 17.07万 - 项目类别:
Efficacy of ethanol adjuvant therapy after resection of malignant soft tissue tumors
恶性软组织肿瘤切除术后乙醇辅助治疗的疗效
- 批准号:
22K09407 - 财政年份:2022
- 资助金额:
$ 17.07万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of immune response cells and development of novel adjuvant therapy for sublingual immunotherapy
免疫应答细胞的鉴定和舌下免疫治疗新型辅助疗法的开发
- 批准号:
21KK0287 - 财政年份:2022
- 资助金额:
$ 17.07万 - 项目类别:
Fund for the Promotion of Joint International Research (Fostering Joint International Research (A))
Pursuing molecular biomarkers to guide adjuvant therapy for HPV+ head and neck cancers after transoral robotic surgery
寻找分子生物标志物来指导经口机器人手术后 HPV 头颈癌的辅助治疗
- 批准号:
10357120 - 财政年份:2022
- 资助金额:
$ 17.07万 - 项目类别:
Biomarker research using two prospective studies on preoperative and postoperative adjuvant therapy for pancreatic cancer
使用两项关于胰腺癌术前和术后辅助治疗的前瞻性研究进行生物标志物研究
- 批准号:
21K08700 - 财政年份:2021
- 资助金额:
$ 17.07万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Personalized Resistant Starch as an Adjuvant Therapy for Pediatric Inflammatory Bowel Disease
个性化抗性淀粉作为小儿炎症性肠病的辅助治疗
- 批准号:
437315 - 财政年份:2020
- 资助金额:
$ 17.07万 - 项目类别:
Studentship Programs
Tailored adjuvant therapy in POLE-mutated and p53-wildtype early stage endometrial cancer (TAPER)
POLE 突变和 p53 野生型早期子宫内膜癌 (TAPER) 的定制辅助治疗
- 批准号:
435603 - 财政年份:2020
- 资助金额:
$ 17.07万 - 项目类别:
Operating Grants